

## Innovative, Integrated Translational Research

Since its founding in 2006, CBSET has partnered with more than 400 MedTech and BioTech companies, including start-ups and industry-leading corporations, enabling them to initiate clinical studies and gain subsequent US and OUS market approvals for their novel therapeutic, imaging, and diagnostic technologies.

- **CBSET is a translational research institute** headquartered in Lexington, MA, dedicated to preclinical research, education, and the advancement of early-stage biomedical technologies. CBSET’s mission is to help medical device and biotechnology companies develop unique tools and new methods to promote early diagnosis of, and develop innovative treatments for complex diseases.
- **CBSET specializes** in the development and application of novel, minimally invasive and surgical techniques in the fields of cardiology, electrophysiology, wound healing, regenerative medicine, endoscopy/laparoscopy, orthopedics, drug and device safety, drug and device delivery, and diagnostic imaging.
- **CBSET provides** GLP (Good Laboratory Practice) and non-GLP research services ranging from early product evaluation through lead optimization and preclinical safety, to physician assessment and training. CBSET’s world-class regulatory and scientific expertise helps transform early-stage concepts into novel therapies.
- **CBSET’s GLP-compliant, AAALAC-accredited facilities** include a 40,000 sq ft state-of-the-art facility in Lexington, and a newly refurbished 22,000 sq ft facility in Grafton, featuring vivaria, catheterization/imaging labs, surgical suites, and dedicated labs for necropsy, histopathology, SEM, and biomechanics. CBSET offers the latest equipment for fluoroscopy, echocardiography (TEE/TTE), electrophysiology, IVUS, optical coherence tomography (OCT), endoscopy/laparoscopy, surgical video recording, histology, microradiography, and SEM (Scanning Electron Microscopy).
- **CBSET’s professional staff** includes PhDs, DVMs and recognized experts in device and drug safety, surgery, imaging, specialized histopathology and pathology, veterinary medicine, pharmacology, lead optimization, pharmacokinetics and drug metabolism, and regulatory consulting. These individuals provide the basis for successful scientific collaborations, rapid concept advancements, unparalleled consulting services, and expert dissemination of information and findings to regulatory and scientific bodies.

### **CBSET has been the preclinical partner of choice for more than 400 companies.**

Since its founding, CBSET has become the leader in preclinical biomedical research in critically important therapeutic fields such as interventional cardiology, renal disease and dialysis, chronic drug-resistant hypertension, women’s health, minimally invasive surgery, orthopedics, biological and synthetic tissue repair, drug delivery, bioresorbable devices, combination medical devices, and drug-eluting products.



Peter Markham, CEO

*Our mission is to elevate scientific and medical innovation through creative collaborations with our sponsors and partners that forge new frontiers for improving lives.*

### **MANAGEMENT TEAM**

**Peter M. Markham**  
 Founder, President, CEO

**Haim Danenberg, MD**  
 Chief Scientific Adviser

**John Keating, DVM, DACVP**  
 VP, Pathology

**Misty J. Williams-Fritze, DVM**  
 Director, Veterinary Services

**Michael Naimark**  
 Director, Business Development

**Rami Tzafiriri, PhD**  
 Director, Research and Innovation

**Nicola Perry, BVSc**  
 Director, Pathology Lab Operations

**Taimi Caron**  
 Director, Regulatory Compliance

**Shannon Tierney**  
 Director, Medical Writing and HR

### **BOARD OF DIRECTORS**

**Elazer Edelman, MD, PhD (Chair)**  
 Harvard-MIT Biomedical Eng. Center

**Peter M. Markham**  
 CEO, CBSET

**Adam Groothuis, PhD**  
 VP, Medical Affairs, Mitralign

**Campbell Rogers, MD**  
 CMO, HeartFlow

### **What Sponsors say about CBSET...**

*“We chose to partner with CBSET because they can provide expert research support for all phases of biomedical discovery and development research.”*

**Ray Cohen, Vessix Vascular**

*“As a European company, we were very impressed with CBSET’s expertise and willingness to work as a team to satisfy the requirements of GLP safety and efficacy studies from start to finish.”*

**Barry Russell, neoSurgical**